DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
GDC-0349 is an investigational drug.
There have been 178 clinical trials for GDC-0349. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2010.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lymphoma. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.
Recent Clinical Trials for GDC-0349
|Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL||Kazia Therapeutics Limited||Phase 2|
|Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL||Lakshmi Nayak||Phase 2|
|A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy||Shanghai Jiao Tong University School of Medicine||Phase 2|